Q1 EPS Estimates for Haemonetics Cut by Zacks Research

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research decreased their Q1 2026 EPS estimates for shares of Haemonetics in a research report issued to clients and investors on Thursday, June 5th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $1.01 per share for the quarter, down from their previous estimate of $1.03. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2026 earnings at $1.16 EPS, FY2026 earnings at $4.84 EPS, Q2 2027 earnings at $1.31 EPS, FY2027 earnings at $5.41 EPS and FY2028 earnings at $6.02 EPS.

A number of other research analysts have also weighed in on the company. Raymond James reissued a “strong-buy” rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price objective on shares of Haemonetics in a report on Tuesday, May 20th. Needham & Company LLC dropped their price objective on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Finally, Wall Street Zen downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.89.

Haemonetics Trading Up 0.7%

Shares of Haemonetics stock opened at $72.18 on Monday. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics has a 12-month low of $55.30 and a 12-month high of $94.99. The firm has a market capitalization of $3.47 billion, a price-to-earnings ratio of 28.42, a PEG ratio of 1.11 and a beta of 0.36. The firm’s 50 day simple moving average is $64.42 and its two-hundred day simple moving average is $69.40.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.90 EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Empowered Funds LLC acquired a new position in shares of Haemonetics in the fourth quarter valued at approximately $319,000. Norges Bank acquired a new position in shares of Haemonetics in the fourth quarter valued at approximately $32,803,000. Voya Investment Management LLC grew its holdings in shares of Haemonetics by 820.5% in the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier’s stock valued at $24,748,000 after purchasing an additional 282,521 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Haemonetics by 0.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier’s stock valued at $62,802,000 after purchasing an additional 5,668 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Haemonetics by 9.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier’s stock valued at $3,753,000 after purchasing an additional 4,217 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.